Oberweis Asset Management Inc. Grows Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Oberweis Asset Management Inc. increased its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 50.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,600 shares of the specialty pharmaceutical company's stock after buying an additional 22,100 shares during the quarter. Oberweis Asset Management Inc. owned about 0.31% of ANI Pharmaceuticals worth $3,626,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. US Bancorp DE increased its holdings in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after purchasing an additional 531 shares during the period. KBC Group NV raised its position in ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after buying an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in ANI Pharmaceuticals during the 4th quarter valued at approximately $166,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after acquiring an additional 412 shares during the last quarter. Finally, Integrated Quantitative Investments LLC acquired a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth $271,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on ANIP shares. HC Wainwright reaffirmed a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. StockNews.com lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target for the company. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research note on Monday, April 21st. Finally, Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock traded down $0.01 during mid-day trading on Wednesday, reaching $70.75. 90,591 shares of the stock traded hands, compared to its average volume of 277,531. The stock has a market capitalization of $1.54 billion, a PE ratio of -128.64 and a beta of 0.49. The business has a 50-day moving average of $64.68 and a 200 day moving average of $60.06. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $72.57. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares in the company, valued at approximately $4,131,164.80. This represents a 1.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,200 shares of company stock valued at $197,792. 12.70% of the stock is owned by insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.